GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (FRA:DU8) » Definitions » 5-Year ROIIC %

Genetic Technologies (FRA:DU8) 5-Year ROIIC % : -126.67% (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Genetic Technologies 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Genetic Technologies's 5-Year ROIIC % for the quarter that ended in Jun. 2024 was -126.67%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Genetic Technologies's 5-Year ROIIC % or its related term are showing as below:

FRA:DU8's 5-Year ROIIC % is ranked worse than
91.83% of 208 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.925 vs FRA:DU8: -126.67

Genetic Technologies 5-Year ROIIC % Historical Data

The historical data trend for Genetic Technologies's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies 5-Year ROIIC % Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -901.68 -132.72 -17.05 -92.01 -126.67

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -126.67 -

Competitive Comparison of Genetic Technologies's 5-Year ROIIC %

For the Diagnostics & Research subindustry, Genetic Technologies's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's 5-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's 5-Year ROIIC % falls into.



Genetic Technologies 5-Year ROIIC % Calculation

Genetic Technologies's 5-Year ROIIC % for the quarter that ended in Jun. 2024 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -7.532 (Jun. 2024) - -4.313 (Jun. 2019) )/( 2.873 (Jun. 2024) - 0.343 (Jun. 2019) )
=-3.219/2.53
=-127.23%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Genetic Technologies  (FRA:DU8) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Genetic Technologies 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies Headlines

No Headlines